Zymeworks Inc. (ZYME)

USD 12.74

(-4.71%)

Operating Expenses Summary of Zymeworks Inc.

Zymeworks Inc.'s latest annual operating expenses in 2023 was 196.76 Million USD , down -24.09% from previous year.
Zymeworks Inc.'s latest quarterly operating expenses in 2024 Q2 was 42.31 Million USD , down -11.54% from previous quarter.
Zymeworks Inc. reported a annual operating expenses of 281.95 Million USD in annual operating expenses 2022, up 16.36% from previous year.
Zymeworks Inc. reported a annual operating expenses of 242.31 Million CAD in annual operating expenses 2021, up 7.02% from previous year.
Zymeworks Inc. reported a quarterly operating expenses of 47.83 Million USD for 2024 Q1, up 18.69% from previous quarter.
Zymeworks Inc. reported a quarterly operating expenses of 50.2 Billion USD for 2024 Q3, up 12.36% from previous quarter.

Annual Operating Expenses Chart of Zymeworks Inc. (2023 - 2014)

Historical Annual Operating Expenses of Zymeworks Inc. (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	196.76 Million USD	-24.09%
2022	281.95 Million USD	16.36%
2021	242.31 Million CAD	7.02%
2020	226.41 Million USD	25.73%
2019	180.07 Million USD	109.04%
2018	86.14 Million USD	45.46%
2017	59.22 Million USD	23.11%
2016	48.1 Million USD	62.41%
2015	29.62 Million USD	105.44%
2014	14.41 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	42.31 Million USD	-11.54%
2024 Q1	47.83 Million USD	18.69%
2024 Q3	50.2 Billion USD	12.36%
2023 Q3	49.74 Million USD	-18.61%
2023 Q1	62.85 Million USD	-24.36%
2023 Q2	61.11 Million USD	-2.77%
2023 FY	214.01 Million USD	-24.09%
2023 Q4	40.3 Million USD	-18.98%
2022 Q2	71.26 Million USD	-4.47%
2022 FY	281.95 Million USD	16.36%
2022 Q4	83.09 Million USD	56.82%
2022 Q3	52.98 Million USD	-25.65%
2022 Q1	74.6 Million USD	22.86%
2021 Q4	60.71 Million CAD	-7.1%
2021 Q2	70.65 Million USD	55.02%
2021 FY	242.31 Million CAD	7.02%
2021 Q1	45.57 Million USD	-14.37%
2021 Q3	65.35 Million USD	-7.5%
2020 Q2	52.7 Million USD	19.39%
2020 Q1	44.14 Million USD	-41.62%
2020 Q4	53.22 Million USD	-30.28%
2020 FY	226.41 Million USD	25.73%
2020 Q3	76.33 Million USD	44.83%
2019 Q1	26.47 Million USD	29.86%
2019 FY	180.07 Million USD	109.04%
2019 Q4	75.62 Million USD	521.28%
2019 Q3	12.17 Million USD	-66.69%
2019 Q2	36.54 Million USD	38.02%
2018 Q3	21.58 Million USD	-10.11%
2018 Q4	20.39 Million USD	-5.55%
2018 FY	86.14 Million USD	45.46%
2018 Q1	20.15 Million USD	20.41%
2018 Q2	24.01 Million USD	19.18%
2017 Q1	15.09 Million USD	18.24%
2017 Q2	10.57 Million USD	-29.97%
2017 Q3	16.81 Million USD	59.03%
2017 Q4	16.73 Million USD	-0.48%
2017 FY	59.22 Million USD	23.11%
2016 Q3	12.45 Million USD	-3.29%
2016 Q2	12.87 Million USD	28.78%
2016 Q1	10 Million USD	614.87%
2016 FY	48.1 Million USD	62.41%
2016 Q4	12.77 Million USD	2.53%
2015 FY	29.62 Million USD	105.44%
2015 Q4	1.39 Million USD	0.0%
2014 FY	14.41 Million USD	0.0%

Peer Operating Expenses Comparison of Zymeworks Inc.

Name	Operating Expenses	Operating Expenses Difference
ADC Therapeutics SA	233.01 Million USD	15.559%
Alto Neuroscience, Inc.	37.8 Million USD	-420.405%
Annovis Bio, Inc.	45.03 Million USD	-336.905%
Biohaven Pharmaceutical Holding Company Ltd.	436.05 Million USD	54.877%
Ginkgo Bioworks Holdings, Inc.	1.1 Billion USD	82.248%
Nuvation Bio Inc.	99.82 Million USD	-97.111%
Nuvation Bio Inc.	99.82 Million USD	-97.111%
Arcus Biosciences, Inc.	457 Million USD	56.945%
Theriva Biologics, Inc.	21.43 Million USD	-818.109%